Denali Therapeutics (DNLI) Getting Somewhat Negative Press Coverage, Analysis Shows

News articles about Denali Therapeutics (NASDAQ:DNLI) have trended somewhat negative on Monday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Denali Therapeutics earned a daily sentiment score of -0.05 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.1819544707044 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

Denali Therapeutics (NASDAQ:DNLI) opened at $21.34 on Monday. Denali Therapeutics has a 1-year low of $14.72 and a 1-year high of $25.79.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Monday, March 19th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.47). equities research analysts forecast that Denali Therapeutics will post -0.87 earnings per share for the current year.

A number of equities research analysts recently weighed in on the stock. Evercore ISI assumed coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $23.00 price target for the company. Morgan Stanley assumed coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They set an “overweight” rating and a $25.00 price target for the company. JPMorgan Chase & Co. assumed coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They set an “overweight” rating and a $24.00 price target for the company. Finally, Goldman Sachs assumed coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They set a “neutral” rating for the company.

ILLEGAL ACTIVITY WARNING: “Denali Therapeutics (DNLI) Getting Somewhat Negative Press Coverage, Analysis Shows” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3301094/denali-therapeutics-dnli-getting-somewhat-negative-press-coverage-analysis-shows.html.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Asbury Automotive Group  Given Daily News Impact Rating of 0.39
Asbury Automotive Group Given Daily News Impact Rating of 0.39
Aramark  Rating Lowered to Sell at Zacks Investment Research
Aramark Rating Lowered to Sell at Zacks Investment Research
Zacks Investment Research Downgrades Bristow Group  to Hold
Zacks Investment Research Downgrades Bristow Group to Hold
Shell Midstream Partners  Earns Buy Rating from Analysts at Deutsche Bank
Shell Midstream Partners Earns Buy Rating from Analysts at Deutsche Bank
Enterprise Products  Coverage Initiated at Deutsche Bank
Enterprise Products Coverage Initiated at Deutsche Bank
Bryn Mawr Bank  Stock Rating Reaffirmed by Keefe, Bruyette & Woods
Bryn Mawr Bank Stock Rating Reaffirmed by Keefe, Bruyette & Woods


© 2006-2018 Ticker Report. Google+.